TY  - JOUR
AU  - Sekulovic, L. Kandolf
AU  - Peris, K.
AU  - Hauschild, A.
AU  - Stratigos, A.
AU  - Grob, J. -J.
AU  - Nathan, P.
AU  - Dummer, R.
AU  - Forsea, A. -M.
AU  - Hoeller, C.
AU  - Gogas, H.
AU  - Demidov, L.
AU  - Lebbe, C.
AU  - Blank, C.
AU  - Olah, J.
AU  - Bastholt, L.
AU  - Herceg, D.
AU  - Neyns, B.
AU  - Vieira, R.
AU  - Hansson, J.
AU  - Rutkowski, P.
AU  - Krajsova, I.
AU  - Bylaite-Bucinskiene, M.
AU  - Zalaudek, I.
AU  - Maric-Brozic, J.
AU  - Babovic, N.
AU  - Banjin, M.
AU  - Putnik, K.
AU  - Weinlich, G.
AU  - Todorovic, V.
AU  - Kirov, K.
AU  - Ocvirk, J.
AU  - Zhukavets, A.
AU  - Kukushkina, M.
AU  - De La Cruz Merino, L.
AU  - Ymeri, A.
AU  - Risteski, M.
AU  - Garbe, C.
PY  - 2017
DO  - 10.1016/j.ejca.2017.01.012
SN  - 0959-8049
UR  - http://hdl.handle.net/10668/18767
T2  - European journal of cancer
AB  - Background: Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and...
LA  - en
PB  - Elsevier sci ltd
KW  - Access
KW  - Innovative medicines
KW  - Metastatic melanoma
KW  - Treatment
KW  - Immuno oncology
KW  - Targeted therapy
KW  - Health expenditure per capita
KW  - Human development index
KW  - Health-care
KW  - Malignant-melanoma
KW  - Cancer incidence
KW  - Disparities
KW  - Mortality
KW  - Medicines
KW  - Diagnosis
KW  - Survival
KW  - Reimbursement
KW  - Union
TI  - More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
TY  - research article
VL  - 75
ER  -